Buchumschlag

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Harter, Philipp (VerfasserIn) , Bogner, Gerhard (VerfasserIn) , Chiva, Luis (VerfasserIn) , Cibula, David (VerfasserIn) , Concin, Nicole (VerfasserIn) , Fotopoulou, Christina (VerfasserIn) , Gonzalez-Martin, Antonio (VerfasserIn) , Guyon, Frederic (VerfasserIn) , Heinzelmann-Schwarz, Viola (VerfasserIn) , Kridelka, Frederic (VerfasserIn) , Mahner, Sven (VerfasserIn) , Marmé, Frederik (VerfasserIn) , Marth, Christian (VerfasserIn) , Morice, Philippe (VerfasserIn) , Novák, Zoltán (VerfasserIn) , Papadia, Andrea (VerfasserIn) , Ray-Coquard, Isabelle (VerfasserIn) , Redecha, Mikuláš (VerfasserIn) , Redondo, Andres (VerfasserIn) , Schwameis, Richard (VerfasserIn) , Sehouli, Jalid (VerfasserIn) , Undurraga, Manuela (VerfasserIn) , Van Gorp, Toon (VerfasserIn) , Vergote, Ignace (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 2024
In: Bulletin du cancer
Year: 2024, Jahrgang: 111, Heft: 3, Pages: 277-284
ISSN:1769-6917
DOI:10.1016/j.bulcan.2023.02.011
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.bulcan.2023.02.011
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S000745512300098X
Volltext
Verfasserangaben:Philipp Harter, Gerhard Bogner, Luis Chiva, David Cibula, Nicole Concin, Christina Fotopoulou, Antonio Gonzalez-Martin, Frederic Guyon, Viola Heinzelmann-Schwarz, Frederic Kridelka, Sven Mahner, Frederik Marmé, Christian Marth, Philippe Morice, Zoltán Novák, Andrea Papadia, Isabelle Ray-Coquard, Mikuláš Redecha, Andres Redondo, Richard Schwameis, Jalid Sehouli, Manuela Undurraga, Toon Van Gorp, Ignace Vergote
Beschreibung
Zusammenfassung:An international joint statement about the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer was published in 2016, warning about the uncritical use of HIPEC outside controlled studies. This statement has now been updated after the most recent literature was reviewed by the participating study groups and societies. HIPEC became a treatment option in patients with advanced colon cancer after positive results of a randomized trial comparing surgery and HIPEC versus palliative treatment alone. Although this trial did not compare the added value of HIPEC to surgery alone, HIPEC for the treatment of peritoneal metastases was in the subsequent years generalized to many other cancer types associated with peritoneal carcinomatosis including epithelial ovarian cancer (EOC). In the meantime, new evidence from prospective randomized trials specifically for EOC-patients emerged, with however contradicting results and several quality aspects that made the interpretation of their findings critical. Moreover, three additional trials in colorectal cancer failed to confirm the previously presumed survival benefit through the implementation of HIPEC in peritoneally disseminated colorectal cancers. Based on a still unclear and inconsistent landscape, the authors conclude that HIPEC should remain within the remit of clinical trials for EOC-patients. Available evidence is not yet sufficient to justify its broad endorsement into the routine clinical practice.
Beschreibung:Online verfügbar: 24. März 2023, Artikelversion: 4. März 2024
Gesehen am 09.01.2025
Beschreibung:Online Resource
ISSN:1769-6917
DOI:10.1016/j.bulcan.2023.02.011

Ähnliche Einträge